Macular degeneration is a progressive eye condition that affects millions worldwide, causing loss of central vision but rarely leading to complete blindness. While there is no cure, modern medicine offers a variety of treatment options ranging from dietary supplements to advanced injections and innovative therapies being tested in clinical trials. Understanding what treatments are available can help preserve vision and maintain quality of life for years to come.

How treatment helps preserve your vision

The primary goal when treating macular degeneration is to slow the progression of vision loss and help maintain the central vision you need for daily activities like reading, driving, and recognizing faces. Treatment does not restore vision that has already been permanently lost, but it can prevent further damage and, in some cases, significantly slow down the worsening of the condition. The approach taken depends heavily on which type of macular degeneration you have—whether it’s the more common dry form or the more aggressive wet form—and at what stage your disease is when it’s detected.

Both types of macular degeneration affect the macula, which is the central part of the retina responsible for sharp, straight-ahead vision. In dry macular degeneration, tiny protein deposits called drusen build up under the macula, causing it to thin gradually over time. This process usually happens slowly, progressing through early, intermediate, and late stages. Wet macular degeneration occurs when abnormal blood vessels grow beneath the retina and leak fluid and blood, which can cause rapid and severe vision loss. About 90% of people with macular degeneration have the dry form, while roughly 10% develop the wet form, which is always considered an advanced stage of the disease.

What makes early detection so crucial is that symptoms may not appear until the disease has already progressed significantly. Many people with early-stage dry macular degeneration have no noticeable vision changes at all. By the time someone notices that straight lines appear wavy or that there’s a blurry spot in the center of their vision, the disease may have advanced. That’s why regular eye exams, especially for people over 55, are essential even when vision seems perfectly fine. Healthcare professionals, including optometrists and ophthalmologists, work together to monitor changes in your eyes and recommend treatment as soon as it becomes necessary.

Treatment is highly personalized. Your eye care provider will consider your age, overall health, the specific characteristics of your macular degeneration, and how fast the disease is progressing. Some treatments are designed to support the health of the retina and slow down damage, while others are aimed at stopping abnormal blood vessel growth or reducing inflammation. While standard treatments approved by medical societies are the foundation of care, ongoing research into new therapies—including drugs currently being tested in clinical trials—offers hope for even better options in the future.

Standard treatment approaches

Treating dry macular degeneration

Currently, there is no approved medical treatment that can cure or reverse dry macular degeneration in its early or intermediate stages. However, that doesn’t mean there’s nothing you can do. For people with intermediate dry macular degeneration, clinical guidelines recommend taking a specific combination of dietary supplements known as the AREDS2 formula. This formula was developed based on large clinical trials that showed it could reduce the risk of progression to advanced stages of the disease.

The AREDS2 supplement contains vitamins C and E, zinc, copper, and two plant-based nutrients called lutein and zeaxanthin. These nutrients support the health of the retina and help protect the macula from further damage. The supplement doesn’t restore lost vision, but it may slow down the rate at which the disease worsens, giving people more years of functional vision. The formula is available over the counter, but it’s important to talk to your doctor before starting any supplement regimen, especially if you have other health conditions or take other medications.

Beyond supplements, lifestyle modifications play a significant role in managing dry macular degeneration. Eating a healthy diet rich in leafy green vegetables like spinach and kale, foods high in omega-3 fatty acids such as salmon and other fatty fish, and colorful fruits can provide additional nutrients that support eye health. Quitting smoking is one of the most impactful changes you can make, as smoking significantly increases the risk of macular degeneration and speeds up its progression. Controlling blood pressure and cholesterol with medication or lifestyle changes also helps protect the blood vessels in your eyes.

Regular monitoring is essential. Even if you’re not receiving active medical treatment for dry macular degeneration, your eye doctor will want to see you regularly to track any changes. You may be given an Amsler grid, a simple visual test you can use at home to check for subtle changes in your central vision. If you notice any new distortions or blank spots when looking at the grid, it’s a signal to contact your doctor right away.

Treating wet macular degeneration

Wet macular degeneration requires more aggressive and timely treatment because it can cause rapid vision loss within weeks if left untreated. The cornerstone of treatment for wet macular degeneration is a class of medications called anti-VEGF drugs. VEGF stands for vascular endothelial growth factor, a protein that promotes the growth of new blood vessels. In wet macular degeneration, too much VEGF leads to the formation of abnormal, leaky blood vessels under the retina.

Anti-VEGF medications work by blocking this protein, which stops the growth of these abnormal vessels and reduces fluid leakage. The drugs are delivered directly into the eye through a series of injections. While the idea of an injection into the eye may sound frightening, the procedure is performed using numbing drops and is generally well-tolerated. The injections are typically given in a doctor’s office or clinic, and most people experience only mild discomfort.

Several anti-VEGF drugs are currently used to treat wet macular degeneration. These include ranibizumab (marketed as Lucentis), aflibercept (Eylea), bevacizumab (Avastin), brolucizumab (Beovu), and faricimab (Vabysmo). Each of these medications has been shown to slow or stop vision loss in most people with wet macular degeneration, and some people even experience modest improvements in vision. The frequency of injections varies depending on the specific drug and how your eyes respond to treatment. Some people need injections every month, while others can go longer between treatments.

The duration of treatment with anti-VEGF drugs is often long-term. Many people need ongoing injections for months or even years to keep the disease under control. Your doctor will monitor your response to treatment using eye exams and imaging tests to determine how often you need injections. Missing scheduled treatments can allow the abnormal blood vessels to regrow, leading to renewed leakage and vision loss.

Side effects from anti-VEGF injections are generally mild but can include temporary discomfort, redness, or a feeling of pressure in the eye. More serious complications, such as infection or increased eye pressure, are rare but possible. Your doctor will discuss the risks and benefits of treatment with you and monitor for any problems.

In addition to anti-VEGF injections, two other treatment options are occasionally used for wet macular degeneration. Photodynamic therapy combines a light-sensitive drug injected into the bloodstream with a special laser treatment. The drug accumulates in the abnormal blood vessels, and when the laser is applied, it activates the drug, causing the vessels to close. This treatment is less commonly used today because anti-VEGF injections tend to be more effective. Laser surgery can also be used to destroy abnormal blood vessels, but it carries a risk of damaging surrounding healthy tissue, so it’s reserved for specific cases.

Emerging treatments in clinical trials

Research into new treatments for macular degeneration is ongoing around the world, with many promising therapies currently being tested in clinical trials. These trials are essential for developing better, more effective treatments that could one day replace or complement the standard therapies we have today. Clinical trials typically progress through three phases: Phase I tests the safety of a new treatment in a small group of people, Phase II evaluates how well it works and continues to monitor safety, and Phase III compares the new treatment to existing standard treatments in larger groups of patients.

New drugs for late-stage dry macular degeneration

One of the most exciting areas of research involves finding treatments for late-stage dry macular degeneration, also known as geographic atrophy. Geographic atrophy occurs when parts of the retina gradually waste away, creating areas of permanent vision loss. Until recently, there were no approved treatments for this condition. However, two new drugs have been approved for use in the United States, and regulatory agencies in other countries are reviewing them.

The first drug is pegcetacoplan, marketed under the name Syfovre. It is produced by the pharmaceutical company Apellis. Pegcetacoplan works by targeting a part of the immune system called the complement pathway, which is believed to play a role in the inflammation and damage that occurs in geographic atrophy. By blocking this pathway, the drug aims to slow down the rate at which the retina deteriorates. Clinical trials showed that people who received monthly or every-other-month injections of pegcetacoplan experienced a slower spread of geographic atrophy compared to those who did not receive the treatment. However, the drug does not restore lost vision, and some trial participants experienced a higher risk of developing wet macular degeneration as a side effect.

The second drug approved in the United States is avacincaptad pegol, marketed as Izervay and produced by Astellas. Like pegcetacoplan, this drug also targets the complement pathway and is administered as an eye injection either monthly or every other month. In clinical trials, avacincaptad pegol showed similar benefits in slowing the progression of geographic atrophy. The drug is currently being reviewed for approval in the United Kingdom and Europe. Both of these drugs represent an important step forward, as they are the first treatments specifically designed to address late-stage dry macular degeneration.

It’s important to understand that while these drugs can slow the worsening of geographic atrophy, they do not reverse damage or improve vision. The goal is to preserve as much remaining vision as possible for as long as possible. Additionally, these treatments are not without risks, and the decision to use them should be made in consultation with your eye care provider, who can help weigh the potential benefits against the possible side effects.

Stem cell and gene therapies under investigation

Another promising area of research involves using stem cells to replace damaged cells in the retina. In macular degeneration, the light-sensitive cells in the macula, called photoreceptors, and the supporting cells beneath them, called the retinal pigment epithelium, gradually die or stop functioning. Researchers are exploring whether stem cells—cells that have the ability to develop into many different cell types—can be used to replace these damaged cells and restore vision.

Clinical trials are currently underway to test stem cell transplants for dry macular degeneration. These trials are typically in the early phases, focusing on safety and determining the best way to deliver the cells to the retina. Some studies involve injecting stem cells directly into the eye, while others are testing patches of retinal cells grown in the lab and then surgically placed under the retina. While stem cell therapy holds great promise, it is still experimental, and it will take several more years of research to determine whether it can become a widely available treatment.

Gene therapy is another innovative approach being explored. Gene therapy involves delivering healthy copies of genes into cells to correct genetic defects or to provide cells with new instructions. In the case of macular degeneration, researchers are investigating whether gene therapy can be used to protect retinal cells from damage or to produce protective proteins that slow disease progression. Some gene therapy trials are focusing on delivering genes that block VEGF production directly into the eye, which could potentially reduce or eliminate the need for frequent anti-VEGF injections in people with wet macular degeneration.

Innovations in drug delivery

One of the challenges with current treatments for wet macular degeneration is the need for frequent injections into the eye. Researchers are working on new ways to deliver medications that could reduce the burden of repeated injections. One such innovation is a sustained-release implant that is placed inside the eye and slowly releases anti-VEGF medication over several months. This type of implant could allow people to go longer between clinic visits while still keeping the disease under control.

An example of this technology is Susvimo, a refillable implant that is surgically placed in the eye and can be refilled with medication during office visits without the need for repeated injections. Clinical trials have shown that this approach can be effective in maintaining vision while reducing the frequency of treatments. However, because it involves a surgical procedure to implant the device, it may not be suitable for everyone.

Participating in clinical trials

Clinical trials are conducted in many locations around the world, including the United States, Europe, and other regions. People with macular degeneration who are interested in participating in a trial can ask their eye doctor about available studies or search for trials through registries maintained by health organizations. Eligibility for clinical trials varies depending on the study, but factors often include the type and stage of macular degeneration, age, and overall health.

Participating in a clinical trial can give you early access to cutting-edge treatments that are not yet available to the general public. However, it’s important to understand that experimental treatments may not work as hoped, and there can be unknown risks. Researchers closely monitor participants for safety, and you will receive detailed information about the study before deciding whether to enroll.

Most common treatment methods

• Dietary supplements
  • AREDS2 formula containing vitamins C and E, zinc, copper, lutein, and zeaxanthin for intermediate dry macular degeneration
  • May slow progression to advanced stages but does not restore lost vision
  • Available over the counter but should be discussed with a doctor before starting
• Anti-VEGF injections
  • Medications like ranibizumab (Lucentis), aflibercept (Eylea), bevacizumab (Avastin), brolucizumab (Beovu), and faricimab (Vabysmo)
  • Block vascular endothelial growth factor to stop abnormal blood vessel growth in wet macular degeneration
  • Administered directly into the eye monthly or at extended intervals
  • Can slow or stop vision loss and sometimes modestly improve vision
• Complement pathway inhibitors
  • Pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay) for late-stage dry macular degeneration with geographic atrophy
  • Target inflammation in the immune system to slow retinal deterioration
  • Given as eye injections monthly or every other month
  • Approved in the United States, under review in other regions
• Photodynamic therapy
  • Combines a light-sensitive drug injected into the bloodstream with laser treatment
  • Drug accumulates in abnormal blood vessels, and laser activates it to close the vessels
  • Less commonly used now due to effectiveness of anti-VEGF injections
• Laser surgery
  • Uses laser to destroy abnormal blood vessels in wet macular degeneration
  • Reserved for specific cases due to risk of damaging surrounding healthy tissue
• Lifestyle modifications
  • Healthy diet rich in leafy greens, fatty fish high in omega-3s, and colorful fruits
  • Quitting smoking to reduce risk and slow progression
  • Controlling blood pressure and cholesterol
  • Protecting eyes from UV light with sunglasses
• Low vision aids and adaptive devices
  • Magnifiers, specialized glasses, and electronic devices to help with daily tasks
  • Enhanced lighting and high-contrast tools for reading and other activities
  • Vision rehabilitation services to learn new techniques for maximizing remaining vision

Living with macular degeneration

Even with the best medical treatments, adjusting to life with macular degeneration can be challenging. The loss of central vision can make everyday activities more difficult, but with the right strategies and tools, most people can maintain a high level of independence and continue doing the things they enjoy. It’s important to remember that macular degeneration does not cause complete blindness—peripheral vision remains intact, which means you can still navigate your environment safely.

One of the first steps in adapting to vision loss is learning to use your remaining vision more effectively. This often involves training yourself to use your peripheral vision, which is called eccentric viewing. With practice, you can learn to look slightly to the side of objects you want to see, using the healthier parts of your retina to compensate for the damaged macula. Vision rehabilitation specialists can teach you these techniques and provide personalized strategies tailored to your specific needs.

Making changes to your home environment can also make a big difference. Improving lighting throughout your home is one of the most effective adjustments. People with macular degeneration often need brighter light to see clearly, especially for tasks like reading or cooking. Use task lighting—lamps or lights that focus directly on what you’re working on—to reduce shadows and glare. LED bulbs labeled as “warm” tend to work well for people with vision impairment because they have less blue tone.

Contrast is another helpful tool. Using contrasting colors can make it easier to distinguish objects. For example, use a dark cutting board when chopping light-colored foods, or place brightly colored tape on the edges of stairs to make them more visible. Paint or mark light switches, doorknobs, and other frequently used items with bright or contrasting colors so they’re easier to find.

Low vision aids and adaptive technology can significantly improve your ability to perform daily tasks. Magnifiers, both handheld and electronic, can make reading easier. Large-print books, audiobooks, and screen readers can help you continue enjoying literature. Voice assistants on smartphones and smart speakers can help you set reminders, check the weather, make phone calls, and even turn on lights without needing to see screens or switches clearly.

Many people with macular degeneration find support through connecting with others who are facing similar challenges. Peer support groups, whether in person or online, provide a space to share experiences, learn new tips, and find emotional support. Organizations dedicated to macular disease offer resources, educational materials, and helplines where you can ask questions and get advice.

It’s also important to address the emotional impact of vision loss. Feelings of frustration, sadness, or anxiety are common, especially in the early stages of adjusting to a diagnosis. Talking to a counselor or therapist who specializes in vision loss can be helpful. Some people also benefit from working with occupational therapists who can assess their needs and recommend specific tools and techniques to make daily life easier.

Staying active and engaged is key to maintaining quality of life. Many hobbies and activities can be adapted to accommodate vision changes. For example, if you enjoy watching television, sitting closer to the screen or using a larger screen can help. If you love knitting or other crafts, better lighting and magnifying tools can make it easier to see fine details. Staying socially connected, exercising regularly, and eating a healthy diet all contribute to overall well-being and help you stay independent.